Should ultrathin strut drug eluting stents be considered the new benchmark for novel coronary stents approval? The complex interplay between stent strut thickness, polymeric carriers and antiproliferative drugs.
Angelo Sante Bongo
Journal of thoracic disease
View on PubMed
Abstract & Figures
Sorry, we couldn't extract an abstract for this paper.
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.
Sorry, we couldn't extract any citations for this paper.
Sorry, we couldn't extract any references for this paper.
Loading similar papers…
Slides referencing similar topics
The Drug Eluting Stent Firestorm
Christian Spaulding + 10 • Oct 26, 2017
Drug Eluting Stents: Balancing Risks and Benefits
Sanjay Kaul • Oct 15, 2017
Importance of Polymer Biocompatibility for Drug Eluting Stent (DES) Outcomes
Josiah N. Wilcox • Aug 28, 2017